Background Co-occurring genomic alterations identified downstream main oncogenic
drivers have become more evident since the introduction of next-generation sequencing …

Dysfunction of epidermal growth factor receptor (EGFR) signalling plays a critical role in the
oncogenesis of non–small‐cell lung cancer (NSCLC). Here, we reported the natural product …

Photodynamic therapy (PDT) in oncology is characterized by low invasiveness, minimal side
effects, and little tissue scarring. Increasing the selectivity of PDT agents toward a cellular …

Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the most
prevalent types of neoplasia worldwide, regardless of gender, with the highest mortality …

Background The gefitinib resistance mechanism in non-small cell lung cancer (NSCLC)
remains unclear, albeit exosomal circular RNA (circRNA) is known to possibly play a vital …

Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85%
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …

Background Epidermal growth factor receptor (EGFR) mutation status is of a major clinical
significance in non-small cell lung cancer (NSCLC) management, as it guides therapeutic …

Purpose: Double inhibition of epidermal growth factor receptor (EGFR) using a tyrosine
kinase inhibitor plus a monoclonal antibody may be a novel treatment strategy for non–small …

Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …

Objectives Recent studies showed prolonged survival for advanced epidermal growth factor
receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) patients treated with both …